Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Sequencing in mCRC
NCT05447715Phase 2Unknown
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in metastatic colorectal cancer (mCRC). Status: unknown.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05447715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05447715.